Galapagos to amend Gilead deal; to spin off innovative medicines unit
Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...
BioPharma Dive6d
Galapagos, after research struggles, will split in two and revamp Gilead deal
Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...
BioSpace6d
Galapagos to Spin Out Innovative Medicines, Regain Gilead Assets
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
MM&M6d
Galapagos to split itself into two companies, lay off 40% of staff
Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...
pharmaphorum6d
Galapagos unveils plan to split, hiving off its drugs unit
Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...
STAT6d
Galapagos to split itself into two companies as part of turnaround plan
The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...
BioSpace5d
Galapagos to Spin Out Innovative Medicines, Lay Off 40%
By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...
Galapagos announces intention to separate into two publicly traded companies
Galapagos (GLPG) announced a planned separation into two entities: a newly to be formed company, which would focus on building a pipeline of ...
PharmiWeb6d
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities
Galapagos NV (Euronext & NASDAQ: GLPG) (“Galapagos” or the “Company”), today announced a planned separation into two entities: a newly to be formed company (to be named at a later date, herein “SpinCo ...